Skip to content
About
Pipeline
MB-105
News & Publications
Menu
About
Pipeline
MB-105
News & Publications
Contact
Contact
About
Pipeline
MB-105
News & Publications
Menu
About
Pipeline
MB-105
News & Publications
Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies
November 13, 2019
9:19 pm
Prev
Previous
Chimeric Antigen Receptors for T-Cell Malignancies
Next
Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL
Next
Scroll Up
